Accelerating research

and development of

new antibiotics and



The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations aimed at developing new antibiotics and alternative therapies, from initial idea to final product. The application is focused on human and animal health, both in prevention and care. While academic institutions have a focus on fundamental and precompetitive research to discover and characterise new antibiotic and alternative leads, NADP provides a platform that facilitates the ensuing public-private collaborations.

Stay informed on NADP and subscribe to our Newsletter.

NADP Partners

The NADP partners are the Centre for Antimicrobial Research (CARES), the Centre for Sustainable Antimicrobials (CeSAM) and the Netherlands Centre for One Health (NCOH).

Read more about the NADP partner organisations here.




NADP is a collaborative effort of its partners CARES, CeSAM and NCOH and is supported by the Dutch Ministry of Health, Welfare, and Sport (VWS). Funding is provided through a financial grant from the Ministry of VWS. NADP is strategically and organisationally embedded within NCOH, in particular within its Strategic Research Theme Tackling Antimicrobial Resistance (NCOH-AMR). The NCOH-AMR is organised through so-called Solution Sets. Within NCOH-AMR, the NADP will provide a platform for public-private partnerships in the Solution Sets "New Antibiotics" and "New Alternatives". While the NCOH has an academic, precompetitive focus and provides the research platform in which antibiotic and alternative leads are discovered and characterised, the NADP facilitates the ensuing public-private collaborations and provides a platform in which academic and industrial partners can meet.

NADP pipeline

Antimicrobial resistance is a global threat for public health. As a result of an overuse of antibiotics, a growing number of bacteria is becoming insensitive to antibiotic treatment. Therefore, diseases that are currently easy to treat, such as lung or bladder infections, could once more become life-threatening.

The resistance to antibiotics is a growing concern in today’s society. The Organisation for Economic Cooperation and Development estimates that world-wide about 700,000 people die each year due to infections caused by drug-resistant bacteria. Since 1987, no new classes of antibiotics have been introduced onto the market. Additional research into new antibiotics, combinatorials, or alternative and preventive treatments, such as vaccines and probiotics, is important in the efforts to combat resistant bacteria.

The development of new drugs involves a great deal of time and research, and comes at a high cost. The return on investment for the development of new antibiotics is low, as these drugs are only used for a short period of time. After years of antibiotic development, the low-hanging fruits have been picked, and it is getting increasingly difficult to find novel compounds. Society urgently calls for major breakthroughs to identify, synthesize and produce new, better antibiotics and alternatives to successfully tackle antimicrobial resistance.

By matching partners for new public-private partnerships, NADP aims to accelerate the development pipeline to fill it with new antibiotics and new in prevention and care, to combat antimicrobial resistance.

Antimicrobial Resistance

Research and development of NADP spans from translational and preclinical research leading to applied and clinical studies.


International initiatives

NADP will engage with EU and international initiatives in order to achieve synergies and focus on strategic priorities. These include among others:

  • A new EU strategy on AMR, plus the ongoing work under the IMI Innovative Medicines Initiative - read more
  • G7/G20 initiative on combatting AMR - read more
  • World Economic Forum: "Antibiotic resistance is the next great global challenge - we must act now" - read more
  • The creation of CARB-X was prioritized in the 2015 US National Action Plan on Combating Antibiotic-Resistant Bacteria (CARB), which called for a biopharmaceutical accelerator to spur pre-clinical product development - read more
  • The Global Antibiotic Research and Development Partnership (GARDP) was established in May 2016 as a joint initiative by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) - read more
  • WHO Global action plan on AMR, including prioritisation of pathogens - read more
  • WHO review of the antibiotics chapter of the WHO Essential Medicines list - read more